VERA — Vera Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $1.48bn
- $890.61m
- 47
- 26
- 40
- 31
Annual income statement for Vera Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 52.2 | 31.7 | 90.9 | 102 | 167 |
| Operating Profit | -52.2 | -31.7 | -90.9 | -102 | -167 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -53.4 | -32.6 | -89.1 | -96 | -152 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -53.4 | -32.6 | -89.1 | -96 | -152 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -53.4 | -32.6 | -89.1 | -96 | -152 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -53.4 | -32.6 | -89.1 | -96 | -152 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.48 | -1.61 | -3.35 | -2.25 | -2.75 |